Affiliation:
1. Clinical Pharmacology and Pharmacometrics, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 8PA, UK
2. Faculty of Medicine, Imperial College London, London SW7 2AZ, UK
Abstract
Ethical regulations and limited paediatric participants are key challenges that contribute to a median delay of 6 years in paediatric mAb approval. To overcome these barriers, modelling and simulation methodologies have been adopted to design optimized paediatric clinical studies and reduce patient burden. The classical modelling approach in paediatric pharmacokinetic studies for regulatory submissions is to apply body weight-based or body surface area-based allometric scaling to adult PK parameters derived from a popPK model to inform the paediatric dosing regimen. However, this approach is limited in its ability to account for the rapidly changing physiology in paediatrics, especially in younger infants. To overcome this limitation, PBPK modelling, which accounts for the ontogeny of key physiological processes in paediatrics, is emerging as an alternative modelling strategy. While only a few mAb PBPK models have been published, PBPK modelling shows great promise demonstrating a similar prediction accuracy to popPK modelling in an Infliximab paediatric case study. To facilitate future PBPK studies, this review consolidated comprehensive data on the ontogeny of key physiological processes in paediatric mAb disposition. To conclude, this review discussed different use-cases for pop-PK and PBPK modelling and how they can complement each other to increase confidence in pharmacokinetic predictions.
Reference76 articles.
1. Development of therapeutic antibodies for the treatment of diseases;Lu;J. Biomed. Sci.,2020
2. Food and Drug Administration (2020, November 30). Bamlanivimab EUA Letter of Authorization, Available online: https://www.fda.gov/media/143602/download.
3. Food and Drug Administration (2020, November 30). Casirivimab and Imdevimab EUA Letter of Authorization, Available online: https://www.fda.gov/media/143891/download.
4. The status of paediatric medicines initiatives around the world––What has happened and what has not?;Hoppu;Eur. J. Clin. Pharmacol.,2012
5. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies;Malik;Expert Opin. Drug Metab. Toxicol.,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献